Physician profile
Jennifer Butt
NPI 1023353745
$5,468.64
in general payments reported to CMS, 2019-2025
36 companies · $553 in 2025
The $553 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $652 · 2021: $596 · 2022: $1,128 · 2023: $1,047 · 2024: $649 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.25 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,050.06 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Avion Pharmaceuticals | $635.53 | 2019-2023 | Balcoltra |
| Agile Therapeutics, INC. | $424.84 | 2022-2024 | Twirla |
| Mayne Pharma Commercial LLC | $317.56 | 2021-2025 | |
| Shield Therapeutics INC | $275.52 | 2023-2025 | Accrufer |
| Hologic Sales and Service, LLC | $221.10 | 2021-2025 | Aptima |
| Therapeuticsmd, INC. | $179.39 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $177.02 | 2019-2020 | |
| Millicent US INC | $167.42 | 2019-2025 | Femlyv, Intrarosa |
| Myovant Sciences INC. | $165.15 | 2021-2022 | |
| Aspira Women'S Health INC | $159.06 | 2022 | |
| Organon LLC | $134.02 | 2022-2025 | Nexplanon |
| Evofem Biosciences, INC. | $131.89 | 2022-2024 | Phexxi |
| Mission Pharmacal Company | $131.42 | 2019-2021 | |
| Kci USA, INC. | $124.17 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $113.42 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Amag Pharmaceuticals, INC. | $103.75 | 2019-2020 | |
| Exeltis, USA INC. | $95.66 | 2019-2025 | Slynd |
| Scynexis, INC. | $93.49 | 2022 | |
| Davol INC. | $81.96 | 2019 | |
| Sumitomo Pharma America, INC. | $78.11 | 2023-2024 | Myfembree |
| Sanofi Pasteur INC. | $68.72 | 2024-2025 | |
| Duchesnay USA Incorporated | $65.23 | 2019 | |
| Dysis Medical, INC. | $56.76 | 2020-2022 | |
| Biogen, INC. | $54.96 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $53.30 | 2019-2021 | |
| Amgen INC. | $52.32 | 2019 | |
| Allergan, INC. | $50.15 | 2019-2020 | |
| Daiichi Sankyo INC. | $41.91 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.54 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $36.96 | 2021-2023 | Exparel |
| Astellas Pharma US INC | $21.98 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.02 | 2025 | |
| Renovia INC | $17.44 | 2019 | |
| Abbott Laboratories | $16.45 | 2024 | Proclaim |
| Mylan Pharmaceuticals INC. | $16.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.